<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HD19A0239F71743DCA9DB4193CE61058E" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 8428 IH: Allowing Greater Access to Safe and Effective Contraception Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-07-19</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 8428</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220719">July 19, 2022</action-date><action-desc><sponsor name-id="H001091">Mrs. Hinson</sponsor> (for herself, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="M000194">Ms. Mace</cosponsor>, <cosponsor name-id="M001159">Mrs. Rodgers of Washington</cosponsor>, and <cosponsor name-id="S001195">Mr. Smith of Missouri</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HWM00">Committee on Ways and Means</committee-name>, and in addition to the Committee on <committee-name committee-id="HIF00">Energy and Commerce</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To allow women greater access to safe and effective oral contraceptive drugs intended for routine use.</official-title></form><legis-body id="HCE7250704F7541A5B98FFAEB7D97CD39" style="OLC"><section section-type="section-one" id="H7BEEE3049F5E4C898BA3843BC07618DA"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Allowing Greater Access to Safe and Effective Contraception Act</short-title></quote>.</text></section><section id="HBECF090EF35046BD9BABA2FA15862E73"><enum>2.</enum><header>Supplemental applications for over-the-counter contraceptive drugs</header><subsection id="HF7A2F72AC28C42FC941CFA3680F7DF57"><enum>(a)</enum><header>Priority review of application</header><text>The Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall give priority review to any supplemental application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(b)</external-xref>) if—</text><paragraph id="H5848BC7E58484FF2A6177E63105CB4B5"><enum>(1)</enum><text>the supplemental application is with respect to an oral contraceptive drug intended for routine use; </text></paragraph><paragraph id="HFD213372393D45FFBF28078AB4260EAF"><enum>(2)</enum><text>the supplemental application is not with respect to any emergency contraceptive drug; and</text></paragraph><paragraph id="HC50544C355CA4724A805CDC7B003BDC6"><enum>(3)</enum><text>if the supplemental application is approved, with respect to individuals aged 18 and older, such drug would not be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>).</text></paragraph></subsection><subsection id="H36710045CDFB4574ADD0B76CB17EC797"><enum>(b)</enum><header>Fee waiver</header><text>The Secretary shall waive the fee under section 736(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379h">21 U.S.C. 379h(a)(1)</external-xref>) with respect to a supplemental application that receives priority review under subsection (a).</text></subsection><subsection id="H066A144A6EB2481991DAADC0943CBEAC"><enum>(c)</enum><header>Over-the-Counter availability</header><text>Notwithstanding any other provision of law, with respect to individuals under age 18, a contraceptive drug that is eligible for priority review under subsection (a) shall be subject to section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/353">21 U.S.C. 353(b)(1)</external-xref>), including after approval of the supplemental application as described in subsection (a)(3).</text></subsection><subsection id="HB8B75003264C4C9390938037D93C7031"><enum>(d)</enum><header>Applicability</header><text>This section applies with respect to a supplemental application described in subsection (a) that—</text><paragraph id="H8159422B53CD4274BEF54D3648D6E1D4"><enum>(1)</enum><text>is submitted before the date of enactment of this Act and remains pending as of such date of enactment; or</text></paragraph><paragraph id="HBADFA8AF679B4466B4906DF744F213A8"><enum>(2)</enum><text>is submitted after such date of enactment.</text></paragraph></subsection></section><section id="H36419C1A0B0943DD9F4F4373B312EFC6"><enum>3.</enum><header>Empowering women to make their own health decisions</header><subsection id="H3BEEFF665D9E4C269E619F278F8145CE"><enum>(a)</enum><header>Repeal of limitations on contributions to flexible spending accounts</header><text><external-xref legal-doc="usc" parsable-cite="usc/26/125">Section 125</external-xref> of the Internal Revenue Code of 1986 is amended by striking subsection (i).</text></subsection><subsection id="HA11667903AFC42EBB62EB953448AB3EB"><enum>(b)</enum><header>Waiver of stockpiling rules</header><text>The Secretary of the Treasury (or the Secretary's delegate) shall issue regulations or other guidance, or revise regulations and other guidance as necessary, to provide that for purposes of health savings accounts under <external-xref legal-doc="usc" parsable-cite="usc/26/223">section 223</external-xref> of the Internal Revenue Code of 1986, Archer MSAs under section 220 of such Code, and health flexible spending arrangements and health reimbursement arrangements for purposes of sections 106 and 125 of such Code, rules prohibiting the purchase of multiples of any item or limiting the number of an item which can be purchased shall not apply to purchases of oral contraceptive drugs described in section 2(a)(1).</text></subsection><subsection id="H9B73B6CD418842E7A5E7C2F9C15B5896"><enum>(c)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall apply to taxable years beginning after December 31, 2021.</text></subsection></section></legis-body></bill> 

